Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

bioAffinity Technologies (BIAF) Operating Income (2022 - 2025)

Historic Operating Income for bioAffinity Technologies (BIAF) over the last 4 years, with Q3 2025 value amounting to -$2.3 million.

  • bioAffinity Technologies' Operating Income fell 1616.03% to -$2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.4 million, marking a year-over-year decrease of 2434.7%. This contributed to the annual value of -$9.0 million for FY2024, which is 1229.39% down from last year.
  • As of Q3 2025, bioAffinity Technologies' Operating Income stood at -$2.3 million, which was down 1616.03% from -$2.5 million recorded in Q2 2025.
  • In the past 5 years, bioAffinity Technologies' Operating Income ranged from a high of -$684119.0 in Q2 2022 and a low of -$2.9 million during Q4 2024
  • Moreover, its 4-year median value for Operating Income was -$2.0 million (2024), whereas its average is -$1.9 million.
  • As far as peak fluctuations go, bioAffinity Technologies' Operating Income tumbled by 15994.75% in 2023, and later soared by 1397.43% in 2024.
  • Quarter analysis of 4 years shows bioAffinity Technologies' Operating Income stood at -$1.6 million in 2022, then crashed by 44.26% to -$2.3 million in 2023, then dropped by 25.79% to -$2.9 million in 2024, then increased by 22.19% to -$2.3 million in 2025.
  • Its Operating Income was -$2.3 million in Q3 2025, compared to -$2.5 million in Q2 2025 and -$2.6 million in Q1 2025.